中草药2026，Vol.57Issue(16)：6226-6232,7.DOI:10.7501/j.issn.0253-2670.2026.16.002
白花败酱中2个新的无环单萜类成分
Two novel acyclic monoterpenoids isolated from Patrinia villosa
摘要
Abstract
Objective To investigate the chemical constituents of the n-butanol fraction of Patrinia villosa.Methods The compounds were isolated and purified by various chromatographic techniques including silica gel,ODS,Sephadex LH-20 gel,and semi-preparative HPLC,and their structures were elucidated by analysis of spectroscopic data.The anti-inflammatory activities were evaluated by against NO production from lipopolysaccharide(LPS)-stimulated RAW264.7 cells.Results A total of 14 compounds were isolated from the n-butanol fraction of P.villosa ethanol extract and identified as(2E,5R,6R)-5,8-dihydroxy-2,6-dimethyl-2-octenoic acid(1),(2E,5R,6R)-8-acetoxy-5-hydroxy-2,6-dimethyl-2-octenoic acid(2),(2E,6R)-8-hydroxy-2,6-dimethyl-2-octenoic acid(3),(6R,7E,9R)-9-hydroxy-4,7-megastigmadien-3-one(4),ethyl chlorogenate(5),ethyl caffeate(6),dihydrosyringenin(7),7S,8S-threo-4,7,9,9'-tetrahydroxy-3,3'-dimethoxy-8-O-4'-neolignan(8),(+)-isolariciresinol(9),(7S,8R)-dihydrodehydrodiconiferyl alcohol(10),ceplignan(11),(+)-syringaresinol(12),salicifoliol(13),and 5-hydroxy-4-(4-hydroxyphenyl)-2(5H)-furanone hydroxy-butenolide(14).Compounds 1 and 2 are new compounds,and their NO inhibition rates at a concentration of 50 μmol/L were(6.16±1.41)％and(11.11±2.10)％,respectively.Conclusion Compounds 1 and 2 are new acyclic monoterpenoids,and namely patrivic acid B and 8-acetylpatrivic acid B.Compounds 3,4,10,11 and 14 were isolated from P.villosa for the first time.Compounds 1 and 2 showed no significant anti-inflammatory activity.关键词
白花败酱/无环单萜/木脂素/抗炎活性/白花败酱酸B/8-乙酰基白花败酱酸B/肥牛木素Key words
Patrinia villosa(Thunb.)Juss./acyclic monoterpenoid/lignin/anti-inflammatory activity/patrivic acid B/8-acetylpatrivic acid B/ceplignan分类
医药卫生引用本文复制引用
张文玲,吴娟,郁阳,刘劲松,王国凯,孙云鹏..白花败酱中2个新的无环单萜类成分[J].中草药,2026,57(16):6226-6232,7.基金项目
国家自然科学基金项目(32400324) （32400324）
安徽省高校学科(专业)带头人培育项目(DTR2023026) （专业）
安徽中医药大学国家中医药管理局高水平中医药重点学科中药化学学科开放课题(HKDCCM2024013) （HKDCCM2024013）
